Café

© 2026 Longbridge｜Terms of Service Privacy Policy

Zai Lab

ZLAB

23.5701.07% ( +0.250 )

Closed: Aug 10, 16:00:00 (EDT)

OverviewOverview OptionsOptions NewsNews PostsPosts FinancialsFinancials ForecastForecast ValuationValuation ShareholdersShareholders ProfileProfile

LongbridgeAI

CICC Keeps Their Buy Rating on Zai Lab Ltd (1ZLB)
Tip Ranks·1 day ago, 09:45 AM
- CICC maintained a Buy rating on Zai Lab Ltd with a price target of HK$ 20.20 in a recent report. - The broader analyst consensus on the stock stands at a Strong Buy alongside an average price target of € 3.03.
ZLAB+1.07%09688+5.51%
Citi Raises Zai Lab Limited TP to USD45, Expects China Business to Stabilize in 2H26
AASTOCKS News·Aug 6 at 11:07 PM
- Citi reported that Zai Lab Limited achieved 2Q product revenue of approximately USD 106 million, up about 11% QoQ and matching market expectations. - The broker raised Zai Lab Limited's US stock target price from USD 44 to USD 45 while maintaining a Buy/High Risk rating. - This adjustment factors in Tivdak's approval from the National Medical Products Administration alongside anticipated pipeline developments and upcoming catalysts.
ZLAB+1.07%09688+5.51%
Zai Lab (NASDAQ:ZLAB) Shares Up 14.5% on Strong Earnings
Market Beat·Aug 6 at 09:40 AM
- Zai Lab shares rose 14.5% to $21.0250 following a stronger-than-expected earnings report for the quarter. - The biopharmaceutical company posted earnings per share of ($0.50) and revenue of $106.31 million, both beating analyst consensus estimates. - Market activity showed a trading volume of 84,247 shares alongside recent insider stock sales by company executives.
ZLAB+1.07%09688+5.51%
Zai Lab | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 106.31 M
Earnings Watch·Aug 6 at 05:36 AM
- Zai Lab Limited released its Q2 2026 financial results, reporting total revenue of $106.3 million and surpassing market expectations. - Product net revenue increased by 11% compared to the previous quarter, driven by the stable performance of ZEJULA and continued sales growth of VYVGART. - The company expects its commercial business to resume meaningful growth in 2027 and plans to submit its first application to U.S. regulators that same year.
ZLAB+1.07%